In this review we summarize the present status of our knowledge on the enzymes involved in the extracellular metabolism of nucleotides and the receptors involved in nucleotide signalling. We focus on the mechanism of the ATP and ADP signalling pathways in glioma C6, representative of the type of nonexcitable cells. In these cells, ATP acts on the P2Y 2 receptor coupled to phospholipase C, whereas ADP on two distinct P2Y receptors: P2Y 1 and P2Y 12 . The former is linked to phospholipase C and the latter is negatively coupled to adenylyl cyclase. The possible cross-talk between the ATP-, ADP-and adenosine-induced pathways, leading to simultaneous regulation of inositol 1,4,5-trisphosphate and cAMP mediated signalling, is discussed.
"nucleotide receptors", although one can still find in the literature their previous designation.
There are three routes by which nucleotides can reach the extracellular compartment (Bodin & Burnstock, 2001 ). The first is lysis of cells, the second, exocytosis. There are numerous arguments that prove that ATP stored in synaptic vesicles is released as a co-transmitter from nerve terminals by exocytosis (Zimmermann, 1994) . The third route, suggested in some non-neuronal cells, could be carrier-mediated ATP release that would involve ATP-binding cassete proteins (ABC), a family of transport ATPases. However, the precise mechanism of this process remains obscure (Bodin & Burnstock, 2001) .
Once released, the nucleotides interact with various nucleotide receptors and finally are degraded by several ecto-enzymes (Grobben et al., 1999) . Nucleotide receptors are divided into two major classes, P1, responding to adenosine, and P2, responding to ATP, ADP, UTP and UDP (Burnstock, 1978) . Since their first cloning in 1993 and 1994, P2 receptors can be further divided into two families: P2X, ligand gated, intrinsic ion channel, ionotropic receptors, and P2Y, G protein-coupled, seven transmembrane domain, metabotropic receptors Boarder & Hourani, 1998; Boeynaems et al., 2000; Dubyak, 1991; Fredholm et al., 1997) .
The present review is focused on the mechanism of action of the nucleotide P2Y metabotropic receptors that respond to ATP and ADP in glioma C6 cells. Attention is also focused on the interaction (cross-talk) that may occur between these receptors.
ECTO-ENZYMES
The released nucleotides are degraded by ecto-enzymes. The term "ecto-enzymes" used in this review concerns the enzymes present on the extracellular side of the cell plasma membrane that exclusively metabolize nucleotides. Several ecto-nucleotidases have been cloned from various tissues, including brain (Chen et al., 1996; Khakh & Kennedy, 1998; Zimmermann, 1994) . Due to their action, ADP, AMP and adenosine are formed from ATP. Extracellular degradation and inactivation of ATP proceeds by a cascade of enzymes: ecto-ATPase (EC 3.6.1.3), ecto-apyrase (EC 3.6.1.5), ecto-nucleotide pyrophosphatase (EC 3.6.1.9) and ecto-5¢-nucleotidase (EC 3.1.3.5). Ecto-ATPase splits off the terminal phosphate and cleaves preferentially ATP into ADP and P i , whereas ecto-apyrase equipotently cleaves ATP, ADP and other nucleoside tri-and diphosphates. Ecto-nucleotide pyrophosphatase converts ATP into AMP and PP i and ecto-5¢-nucleotidase, AMP into adenosine and P i . Ecto-nucleotide pyrophosphatase uses as substrate not only ATP but also UTP, GTP, ADP and UDP. AMP and pyridoxal-phosphate-6-azophenyl-2¢,4¢-disulphonic acid (PP-ADS) are inhibitors of this enzyme (Grobben et al., 1999) . PPADS is also well known inhibitor of ecto-ATPase (Chen et al., 1996) . Ecto-5¢-nucleotidase resides largely on glia (astrocytes, oligodendrocytes and microglia). This enzyme is strongly inhibited by ATP and ADP. In neural tissues, the activity of ecto-5¢-nucleotidase is lower than that of ecto-ATPase and ecto-ADPase. This results in a delayed formation of adenosine after release of ATP (Zimmermann, 1994) . In the synaptic cleft the concentration of ATP is in the micromolar range (Grobben et al., 1999) .
In glioma C6 cells, which are transformed glial cells with a phenotype similar to astrocytes, Grobben et al. (1999) have demonstrated that the main ecto-enzyme that hydrolyzes ATP is ecto-nucleotide pyrophosphatase producing AMP and PP i . The authors found that at 1-10 mM ATP concentration, the hydrolysis of ATP by this enzyme amounted to 75%, whereas at a higher, 100 mM ATP concentration, the degradation of ATP into AMP and PP i decreased to 50%. At such concentration, ATP was also hydrolyzed by ecto-ATPase that produces ADP and P i .
AMP,
formed by ecto-nucleotide pyrophosphatase, was easily converted into adenosine by the ecto-5¢-nucleotidase present in glioma C6 cells. Due to the action of ecto-nucleotide pyrophosphatase and ecto-5¢-nucleotidase, adenosine was found to be the main final product of ATP degradation in this line of cells (Grobben et al., 1999) .
The authors have also described the presence of a nucleoside diphosphate kinase in the conditioned medium of glioma C6 cell cultures that is able to convert ATP + UDP into ADP and UTP (Grobben et al., 1999) . Due to the action of the ecto-enzymes, the P2Y receptor pathways activated by ATP are terminated and the hydrolysis of ATP into AMP and adenosine shifts the signalling pathway from the P2 into P1 nucleotide receptors.
NUCLEOTIDE RECEPTORS
Nucleotide receptors have been classified as P1 and P2 ( Fig. 1 ) and such classification was accepted by the International Union of Pharmacology (IUPHAR) Subcommittee for the Nomenclature and Classification of Purinoceptors (Abbracchio & Burnstock, 1998; Fredholm et al., 1994; .
P1 receptors
P1 receptors respond to adenosine. Adenosine is known to act via four major receptors, A 1 , A 2A , A 2B and A 3 (Fig. 1) , which have been characterized according to their primary sequences and their biochemical and pharmacological properties (Fredholm et al., 1994; Stiles, 1992) . Extracellular ATP and ADP are rapidly broken down by ecto-enzymes to adenosine. However, under stress condition, such as hypoxia when the cellular energetics is depressed, intracellular adenosine production is greatly enhanced and adenosine can be released into the extracellular space by specific transporters (Khakh & Kennedy, 1998; Stiles, 1992) . The released adenosine, similarly as that formed by the action of ecto-enzymes can act on adenosine receptors. It is worth adding that extracellular adenosine can be also transported back into the cell by a specific nucleotide transporter or cross the cell membrane by simple diffusion (Stiles, 1992) . In contrast, extracellular ATP and ADP are unable to cross the cell membrane. Adenosine can be also deaminated by a cytosolic, as well as an extracellular, adenosine deaminase. All of these events cause that adenosine in circulation has a short half-life (Stiles, 1992) .
P1 receptors are seven transmembrane domain, G protein-coupled receptors (Ciruela et al., 1997; Stiles, 1992; Windscheif, 1996) . In contrast to P2, P1 receptors are competitively antagonized by methylxanthines (Stiles, 1992) . Whereas A 1 and A 3 receptors are coupled to protein G i and inhibit adenylyl cyclase, both types of A 2 receptors are coupled to protein G s and stimulate adenylyl cyclase. Activation of A 1 receptor increases also K + conductance by opening diverse K + channels (Belardinelli, 1993; Zimmermann, 1994) , whereas activation of A 2 receptors opens ATP-sensitive K + channels and produces K + Vol. 49 Cross-talk between ATP and ADP receptor pathways 879 efflux in the process that does not involve the pertussis toxin (PTX) sensitive G protein (Furukawa et al., 1993) . In glioma C6 cells, Pianet et al. (1989) showed that adenosine strongly stimulates basal and isoproterenol-elicited cAMP synthesis. These data indicate the presence of the A 2 adenosine receptor positively coupled to adenylyl cyclase in these cells.
P2 receptors
Nucleotides, such as ATP and ADP interact with cell surface P2 receptors (Fig. 1 ). P2 fall into two groups: the intrinsic ion channel P2X receptors and the seven transmembrane domain, G protein-coupled P2Y receptors.
The P2X subtype
At least seven different P2X ionotropic receptors (P2X 1-7 ) have been cloned so far (Fig. 1 ). P2X receptors are characterized by only two membrane-spanning regions, a large cysteine-rich extracellular loop, and both Cand N-termini located intracellularly (Abbracchio & Burnstock, 1998; Khakh & Kennedy, 1998) . As is the case for other ionotropic receptors (nicotinic, GABA A , etc.), functional P2X receptors may be composed of several subunits and may form homo-or hetero-multimers (Windscheif, 1996) . The P2X channel formed by these subunits is permeable to cations, mainly to Ca 2+ . P2X 7 receptor opens non-selective large pores up to 5 nm in diameter. All of these P2X receptors respond to ATP and are even called ATP-gated ion channels. They also respond to ADP and some of them (P2X 1 -P2X 3 ) to UTP and are sensitive to suramin and PPADS as antagonists (Boarder & Hourani, 1998) . a,b-Methylene-ATP interacts with the P2X receptors but is ineffective as an agonist for all P2Y receptors (Boarder & Hourani, 1998) . In glioma C6 cells, addition of a,b-methylene-ATP to the extracellular medium does not produce entry of extracellular Ca 2+ into the cells, which indicates a lack of this type of ionotropic receptors (Saba³a et al., 2001 ).
The P2Y subtype
Metabotropic, G-protein-coupled P2Y receptors fall into the seven transmembrane domain superfamily of receptors with extracellular N-and intracellular C-termini and a large intracellular III loop (Abbracchio & Burnstock, 1998) . Cloning and pharmacological studies revealed seven distinct P2Y receptors: P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6, P2Y 11, P2Y 12 and P2Y 13 (Fig. 1) . Cloned P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 and P2Y 11 receptors activate phospholipase C (PLC) and cause an increase in inositol 1,4,5-trisphosphate (IP 3 ) concentration (Boarder & Hourani, 1998) . The P2Y 12 receptor and its close relative, P2Y 13 receptor, have been cloned only recently (Communi et al., 2001; Hollopeter et al., 2001; Savi et al., 2001; Zhang et al., 2002) . Both are coupled to the inhibition of adenylyl cyclase. Detailed characteristics of the P2Y 12 receptor will be described in one of the following chapters. It was found that the P2Y 1 receptor responds selectively to ADP compared to ATP while ATP may act as a partial antagonist. 2-Methylthio-ATP and 2-methylthio-ADP are also selective agonists of high potency for P2Y 1 receptor, whereas UTP is not effective. In contrast, the P2Y 2 receptor responds both to ATP and UTP, while 2-methylthio-ATP has no effect on its activity. These two receptors are sensitive to suramin but differ in their antagonist selectivity to PPADS (Boarder & Hourani, 1998) . P2Y 1 is blocked by PPADS while P2Y 2 is resistant to this compound. The P2Y 4 and P2Y 6 receptors are selective for UTP and UDP, respectively. The P2Y 4 receptor is activated most potently by UTP, less so by ATP and not at all by nucleoside diphosphates. The P2Y 6 receptor is activated most potently by UDP, weakly by UTP and does not respond to ATP (Boarder & Hourani, 1998; Communi et al., 1996; Lazarowski & Harden, 1994; . The P2Y 6 receptor has been shown 880 R. Czajkowski and J. Barañska 2002 to be expressed in glioma C6-2B cells and is linked to PLC . The P2Y 11 receptor is selective to ATP but not to UTP and UDP (Boarder & Hourani, 1998) .
In glioma C6 cells, ATP has been reported to mediate phosphoinositide turnover (Kitanaka et al., 1992; Lin & Chuang, 1993) . We have also demonstrated that in these cells ATP treatment generates IP 3 and simultaneously results in an increase in intracellular Ca 2+ concentration due to the PLC-mediated release from intracellular stores (Saba³a et al., 1997; .
While the presence of P2Y 2 receptor in glioma C6 cells seems to be generally accepted, the presence of the P2Y 1 receptor that stimulates PLC activity had previously been a subject of serious debate. Studies on glioma C6-2B and C6 cells have shown the presence of a P2Y 1 -like receptor effecting inhibition of adenylyl cyclase but not accumulation of IP 3 and resistant to PPADS (Boarder & Hourani, 1998; Schater et al., 1996; . It has been proposed therefore that two different P2Y 1 receptors exist: one coupled to PLC and blocked by PPADS and another one, native to glioma C6, negatively coupled to adenylyl cyclase. However, this interpretation was questioned by Webb et al. (1996) , who found that cloned rat P2Y 1 receptor cDNA and that derived from glioma C6 are 100% identical in the entire coding region. Thus, the authors suggested that the same P2Y 1 receptor was coupled in different cell types to either PLC activation or to adenylyl cyclase inhibition, as it had been found in glioma C6 cells. However, results from our laboratory revealed that both the P2Y 1 and P2Y 2 receptors co-exist in these cells and both are linked to PLC (Saba³a et al., 1997; et al., 1995; 1999) . When hormones or neurotransmitters interact with plasma membrane receptors that contain seven transmembrane domains and are coupled to protein G q , such interaction results in stimulation of PLCb activity (Fig. 2) . PLC converts phosphatidylinositol (4,5)-bisphosphate (PIP 2 ) into second messengers: IP 3 and diacylglycerol (DAG). IP 3 diffuses through the cytosol to the endoplasmic reticulum (ER) and binds to the IP 3 receptor present at this membrane (Berridge, 1993 (Fig. 2) . This is the second, sustained phase with a more prolonged rise in the cytosolic Ca 2+ . This biphasic process was termed "capacitative Ca 2+ entry" (Berridge, 1995; Putney & Bird, 1993) or "store mediated Ca 2+ entry" (Rosado et al., 2000) and is typical for the nonexcitable type of cells. Ca 2+ entry coupled to the state of filling of the ER Ca 2+ stores is independent on the mechanism of its depletion and can be also caused by thapsigargin, an irreversible inhibitor of the SERCA ATPase, that promotes the leak of Ca 2+ from the ER without IP 3 formation (Fig. 2) . The nature of the signal linking Vol. 49 Cross-talk between ATP and ADP receptor pathways 881 the ER Ca 2+ store with Ca 2+ channels in the plasma membrane is being still debated. Recently, a role of the actin cytoskeleton in this process has been proposed (Rosado et al., 2000; Saba³a et al., 2002) . We have previously shown that glioma C6 cells are characterized by the typical biphasic, capacitative Ca 2+ entry pathway (Barañska et al., 1995; Czajkowski & Barañska, 1999; Czajkowski et al., 2002; Saba³a et al., 1997; (Fig. 3) . In such type of cells, the existence of such a pathway points to PLC activation and IP 3 -mediated signal transduction, responsible for the increase in the intracellular Ca 2+ concentration. (Figs. 3B, 3D, 3F ). Figure 3A shows that the kinetics of ADP-evoked Ca 2+ changes differs from those evoked by ATP and UTP (Figs.  3C, 3E ). The ATP and UTP induced Ca 2+ elevation starts with an initial peak response and is followed by a long sustained plateau phase, whereas the response to ADP is more transient (Fig. 3A) .
We have also shown that cells treated with ATP fail to respond to UTP, indicating that the action of ATP and UTP is non-additive, whereas ADP and UTP effects are additive. Similarly, cross-desensitization between ATP and UTP, but not between ADP and UTP, occurred. The pharmacological properties of nucleotide receptors generating Ca 2+ mobilization in response to various nucleotide analogues indicated the following order of potencies: 2-methyltio-ADP > ADP > 2-methylthio-ATP = 2-chloro-ATP > ATP > UTP. Adenosine, AMP and ab-methylene-ATP, were ineffective (Saba³a et al., 2001 Vol. 49
Cross-talk between ATP and ADP receptor pathways 883 of antagonists indicated that suramin that distinctly blocked both P2Y 1 and P2Y 2 receptors, blocked the effect of ATP, UTP and ADP on the intracellular Ca 2+ rise, whereas PPADS, a selective P2Y 1 but not P2Y 2 antagonist, decreased only the Ca 2+ response to ADP (by 94%) (Saba³a et al., 2001) . A similar effect was observed with MRS2179, a specific and selective antagonist of P2Y 1 receptor . Those data suggested the presence of P2Y 1 and P2Y 2 receptors in glioma C6 cells. To confirm their identity, polymerase chain reaction on reverse transcribed total RNA was employed. The RT-PCR analysis revealed the molecular identity of the P2Y receptors expressed by glioma C6 as both P2Y 1 and P2Y 2 (Fig. 4A) . ADP acts as an agonist on the first and ATP and UTP on the second one. The molecular identity, together with the pharmacological analysis and the typical, biphasic Ca 2+ response, led us to the conclusion that both of these receptors are linked to PLC (Saba³a et al., 2001 ).
The conclusion that in glioma C6, the P2Y 1 receptor stimulates PLC and is effective in the production of IP 3 and release of Ca 2+ from the ER, was supported by direct visualization of a PIP 2 -bound PLCd-PH domain coupled to GFP expressed in these cells . After stimulation of the cells with ADP, the PIP 2 -bound GFP fluorescence at the cell surface was distinctly reduced, indicating the breakdown of PIP 2 by activated PLC . The absence of accumulation of IP 3 in these cells after ADP treatment was the reason for the former belief that in glioma C6 ADP-responding nucleotide receptor stimulation does not lead to PLC activation. This phenomenon was probably caused by the ADP-evoked transient increase in IP 3 level, too short to be examined. It is worth adding that such increase in IP 3 level in glioma C6 cells was observed only at high ADP Czajkowski et al., 2002 (B) ).
concentration and for 30 min stimulation of the cells (Grobben et al., 2001) . In contrast to the PLC activation, ADP-evoked adenylyl cyclase inhibition has long been documented (Boyer et al., 1993) . In glioma C6 cells, ADP, in addition to its effect on the Ca 2+ response, inhibits by 80% the isoproterenol-elicited cAMP accumulation (Saba³a et al., 2001) . This effect was reversed by treatment of the cells with PTX and was insensitive to PPADS. PTX is a specific inhibitor of G i protein coupled to the inhibition of adenylyl cyclase. Those data suggested two possibilities: that in glioma C6 the P2Y 1 receptor is dually coupled to both G q (PLC) and G i (adenylyl cyclase) or that two ADP receptors exist, one, P2Y 1 , coupled to PLC, and the second, P2Y 1 -like, coupled to adenylyl cyclase (Saba³a et al., 2001) .
Most recently, a P2Y receptor that couples to the inhibition of adenylyl cyclase in rat blood platelets, previously termed P2T AC , has been cloned and designated as P2Y 12 (Hollopeter et al., 2001; Savi et al., 2001) . The presence of this receptor has also been reported in glioma C6-2B cells (Jin et al., 2001) . Thus, to differentiate whether ADP interacts with one or with two receptors, we used the antisense oligonucleotide technique and showed that knock-down of the P2Y 1 receptor causes a decrease in the P2Y 1 mRNA level and loss of the receptor-evoked PLC activity . Adenylyl cyclase inhibition by ADP remains unchanged under this condition. To confirm the identity of the P2Y 12 receptor responsible for the inhibition of adenylyl cyclase, PCR on reverse-transcribed total mRNA was employed . Primers were selected to cover the unique sequence of rat platelet P2Y 12 receptor. Figure 4B shows that mRNA of this receptor is expressed and localized in glioma C6 cells. Thus, in these cells, ADP acts on two receptors: P2Y 1 , linked to the stimulation of PLC and Ca 2+ release, and P2Y 12 , negatively coupled to adenylyl cyclase through G i protein.
CROSS-TALK BETWEEN THE ATP AND ADP NUCLEOTIDE RECEPTORS
The biological response to extracellular ATP could be due to ATP or to one of its metabolic products, ADP or adenosine. In glioma C6 cells (Fig. 5) , ATP can interact directly with the P2Y 2 receptor linked to PLC, whereas its metabolic product, ADP, interacts with the P2Y 1 receptor coupled to PLC and with the P2Y 12 receptor, negatively coupled to adenylyl cyclase Saba³a et al., 2001) . Adenosine, interacting with the A 2 type of receptor, stimulates the activity of this enzyme (Pianet et al., 1989) (Fig. 5 ).
In the brain, astrocytes, neurons, and endothelial cells are all ATP-releasing cells. The presence of nucleotide receptors in their plasma membranes points to the function of ATP in the communication between these cells (Zimmermann, 1994) . In neurons, the effect of ATP and adenosine are often opposite. Adenosine, via A 1 receptor inhibits the release of most transmitters, probably by inhibi- Vol. 49 Cross-talk between ATP and ADP receptor pathways 885 tion of presynaptic Ca 2+ channels (Zimmerman, 1994) . In cholinergic nerve terminals isolated from striatum, breakdown of ATP to adenosine by ecto-nucleotidase is a major feedback in the autoinhibitory mechanism depressing further release of ATP. Adenosine, by increasing K + conductance, acts to hyperpolarize neurons. In contrast, ATP depolarizes the neuronal membrane (Illes & Norenberg, 1993) . This depolarization may occur by opening of nonselective cationic channels, or by the action of G protein subunits, activated by P2Y 2 receptor. These events inhibit the resting K + conductance, close K + channels and lead to a long-lasting depolarization (Stiles, 1992; Illes & Norenberg, 1993; Zimmerman, 1994) . Moreover, acting via P2X receptor and producing an influx of Ca 2+ , ATP might play a neurotoxic role, similar to that of glutamate. Adenosine blocks this process. The neuroprotective role of adenosine in cerebral ischemia has long been recognized (Zimmerman, 1994) . However, all of these events concern the effect of adenosine on A 1 receptor that via G i protein inhibits adenylyl cyclase. The A 2A receptor that stimulates adenylyl cyclase, has an opposite function. This type of receptor, present on cholinergic nerve terminals, stimulates acetylcholine release from stratial synaptosomes (Kurokawa et al., 1996) .
In glioma C6 cells, adenosine stimulates adenylyl cyclase activity (Fig. 5) . Chiono et al. (1995) level produced by ATP (Fig. 5) . Perhaps the most significant result described in this review is the evidence that in glioma C6 cells, ADP interacts with two distinct receptors, P2Y 1 and P2Y 12 . The first of them increases the intracellular Ca 2+ level, the second inhibits cAMP synthesis (Fig. 5 ). Since in these cells adenosine, by G s protein, stimulates the activity of adenylyl cyclase, ADP is the only agonist acting on the nucleotide receptor that activates G i protein. This protein not only inhibits adenylyl cyclase by its a subunit, but also by the bg subunits regulates functions of many plasma membrane channels (Hur & Kim, 2002; Selbie & Hill, 1998) . Thus, the cross-talk between the two distinct pathways generated by ADP, the pathways induced by ATP and adenosine, and among all of them, leads to a multiple network of simultaneous regulation of the IP 3 and cAMP mediated signalling. 886 R. Czajkowski and J. Barañska 2002 
